This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC). In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.

READ FULL ARTICLE Curated publisher From Mdlinx